EichorEICHOR
Condition: Zanzalintinib Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Zanzalintinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Phase 1/Phase 2 · 1 location(s) · Indiana University · NCT06937866Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0
Phase 3 · 66 location(s) · Merck Sharp & Dohme LLC · NCT07489495Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carci
Phase 2 · 3 location(s) · Qian Qin · NCT06794229Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Phase 2 · 4 location(s) · M.D. Anderson Cancer Center · NCT06959511Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/Phase 3 · 120 location(s) · Exelixis · NCT06943755Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283731A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Phase 2 · 12 location(s) · Exelixis · NCT07428616Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Phase 2 · 1 location(s) · Kelly Fitzgerald, MD · NCT07043608Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Phase 1 · 1 location(s) · University of Chicago · NCT06912087Zanzalintinib in Men With Aggressive Variant Prostate Cancer
Phase 2 · 1 location(s) · Deepak Kilari · NCT07218666Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06968988Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C
Phase 2 · 4 location(s) · Karie Runcie · NCT06863311A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid
Phase 1 · 11 location(s) · Exelixis · NCT06952010Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Phase 1/Phase 2 · 1 location(s) · Devalingam Mahalingam · NCT07042919Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Phase 2 · 2 location(s) · Washington University School of Medicine · NCT06926634A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6
Phase 3 · 127 location(s) · Merck Sharp & Dohme LLC · NCT07227402Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06957431A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07193550XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Tran
Phase 2 · 1 location(s) · Northwestern University · NCT06571734Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1 · 2 location(s) · Exelixis · NCT06962332Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1 · 4 location(s) · Washington University School of Medicine · NCT06795009
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.